A Brief Review on Medicinal Plants-At-Arms against COVID-19

Table 1

Vaccines under trial for COVID-19, their types, effectiveness, dosage, and storage.

Companies	Country	Name	Type	Trials	Approval	Effective (%)	Dose/gap period (days apart)	Storage/duration (days/weeks)	Reference
FBRI	Russia	EpiVacCorona	Peptide antigens-based	03	01	100	2X/21–28 d	2° to 8°C	[5, 6]
Moderna	USA	mRNA-1273	Lipid nanoparticle (LNP)-encapsulated mRNA	07	40	94.1	2X/28–42 d	2° to 8°C/30 d	[7, 8]
Pfizer/BioNTech	Germany; USA	BNT162b2	Lipid nanoparticle (LNP) formulated, nucleoside modified RNA vaccine	12	68	95	2X/21 d	−25°C to −15°C/2 weeks	[9]
CanSino	China	Ad5-nCoV	Nonreplicating viral vector	06	032	65.7–91%	Single dose	2° to 8°C	[10]
Gamaleya	Russia	Sputnik V	Nonreplicating viral vector	19	45	91.6–100	2X/21 d	2° to 8°C	[11]
Janssen (Johnson & Johnson)	USA	Ad26.COV2.S	Nonreplicating viral vector	08	04	66–85	Single dose	2°to 8°C/3 months	[12]
Oxford/AstraZeneca	UK	AZD1222	Nonreplicating viral vector	22	74	81.3	2X/12 weeks	2° to 8°C/6 months	[13]
Serum Institute of India	India	Covishield	Nonreplicating viral vector	02	17	81.3	2X/12 weeks	2° to 8°C/6 months	[13]
Bharat Biotech	India	Covaxin	Inactivated	0	03	81	2X/21 d	2° to 8°C	[14]
Sinopharm (Beijing)	China	BBIBP-CorV	Inactivated	06	20	79	2X	2° to 8 °C	[15]
Sinopharm (Wuhan)	China	Inactivated (vero cells)	Inactivated	06	02	72.51	2X	2° to 8°C	[16]
Sinovac	China	CoronaVac	Inactivated	13	16	50.4–100	2X	2° to 8°C	[17]
AstraZeneca	Sweden	Vaxzevria	mRNA vaccine	03	121	74	2X/12 weeks	2° to 8°C	[18]
Novavax	USA	Nuvaxovid	Recombinant protein vaccine	03	—	90.4	2X/8 weeks	2° to 8°C	[19]